Pharma Pressreleases

This section covers the managerial aspects in the Pharma industry.

Rapid emergence of MENA biologics industry sees first ever Biopharma Conference and new venue at CPhI Istanbul 2017

Tuesday, January 31, 2017

CPhI Istanbul organised by UBM EMEA in partnership with Pharmaceutical Manufacturers Association of Turkey IEIS returns to Turkey for its fourth edition with a new colocated event BioPh to join ICSE PMEC and InnoPack Taking place 810 March 2017 the fiveinone event is expected to bring together ove..

Charles River Laboratories Announces Progress Update for Collaboration with Moderna Therapeutics

Tuesday, January 31, 2017

Charles River Laboratories International Inc a leading earlystage contract research organization CRO today announced a progress update related to its support of Moderna Therapeutics nonclinical discovery and development efforts Since 2011 Charles River has been a key partner in helping Moderna advan..

Neurotrope Completes Licensing Agreement for Accelerated Synthesis of Alzheimer's Drug Bryostatin-1

Tuesday, January 31, 2017

Neurotrope Inc a clinicalstage biopharmaceutical company developing novel therapies for neurodegenerative diseases including Alzheimer39s disease announced today that it has signed a licensing agreement with Stanford University for an accelerated synthesis of bryostatin1 Prior to this synthetic rout..

Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial

Saturday, January 28, 2017

Aurinia Pharmaceuticals Inc a clinical stage biopharmaceutical company focused on the global immunology market today announced that it has selected Worldwide Clinical Trials Worldwide as its Clinical Research Organization CRO for the AURORA Phase 3 study of volcosporin for the treatment of active lu..

Sunovion’s Latuda® (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia

Saturday, January 28, 2017

Sunovion Pharmaceuticals Inc Sunovion today announced that the US Food and Drug Administration FDA approved the supplemental New Drug Application sNDA for Latuda lurasidone HCI for the treatment of schizophrenia in adolescents aged 13 to 17 years LATUDA is also approved in the US for the treatment o..

Purdue Pharma and Commonwealth of Virginia Partner to Improve Utilization of Prescription Monitoring Program

Friday, January 27, 2017

Purdue Pharma LP Virginia Governor Terry McAuliffe and the Virginia Secretary of Health and Human Resources today announced the formation of a privatepublic partnership to enhance utilization of the state prescription monitoring program PMP as part of the solution to address the opioid crisis The Co..

Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease

Friday, January 27, 2017

Acucela Inc a clinicalstage ophthalmology company and whollyowned subsidiary of Kubota Pharmaceutical Holdings Co Ltd Tokyo 4596 committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide announced today that on J..

Mikron Automation Expands U.S. Headquarters in Metro Denver

Friday, January 27, 2017

Mikron Automation and Denverbased Confluent Development are pleased to announce the expansion of Mikron Automations US headquarters in Arapahoe Countys Dove Valley Business Park The industrial facility will expand to include 19000 square feet of needed space to help support the companys rapid growth..

Vetter Starts Operations in its Center for Visual Inspection and Logistics

Friday, January 27, 2017

Vetter a leading global Contract Development and Manufacturing Organization CDMO for development aseptic filling and final packaging of injectables has announced today that it has begun operations in its expanded Visual Inspection and Logics Center located in Ravensburg The enlargement in which the ..

New Pharmaceutical Business Line Director appointed at Matcon Ltd.

Friday, January 27, 2017

We are pleased to announce that Richard Lockwood has been appointed as our new Pharmaceutical Business Line Director taking over from Shaun Baker who leaves Matcon after 8 years with us In his previous role within our Sales Team Richard worked tirelessly to create successful markets for Matcon in S..

Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases

Wednesday, January 25, 2017

Flex Pharma Inc today announced that it is prioritizing its clinical programs in the severe neurological diseases of amytrophic lateral sclerosis ALS multiple sclerosis MS and peripheral neuropathies such as CharcotMarie Tooth CMT The Company intends to initiate one or two additional proofofconcept ..

ViraCyte Receives Orphan Drug Designation for Viralym-C

Wednesday, January 25, 2017

ViraCyte LLC a clinical stage biopharmaceutical company developing immunotherapies for life threatening infections announced today that the US Food and Drug Administration FDA has granted Orphan Drug designation to ViralymC a ready to administer T cell immunotherapy product for the treatment of cyto..

Onxeo Completes Enrollment in Phase III Study of Livatag® for the Treatment of Hepatocellular Carcinoma

Wednesday, January 25, 2017

Onxeo SA a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases in particular in oncology today announced the completion of enrollment in ReLive the international Phase III clinical trial evaluating Livatag for the treatment of advanced h..

Medical Fair Thailand 2017 The Region’s Most Complete Medical & Healthcare Exhibition Returns! 6 – 8 September 2017

Tuesday, January 24, 2017

The 8th installment of the international exhibition on Hospital Diagnostic Pharmaceutical Medical Rehabilitation Equipment Supplies continues its proud tradition of showonshow growth with an expected international participation of 700 exhibitors 17 national pavilions and country groups as well as ..

Summit on Healthcare Industry to address role of Asia Pacific region in Changing Marketplace

Monday, January 23, 2017

As the global healthcare industry expands at a rapid rate a 20 CAGR by some estimates the Asia Pacific market has undergone profound structural change Previously difficult to access sectors such as the market for medical devices have liberalized substantially and opportunities are now abundant for l..

Swedish Orphan Biovitrum AB: First Patients Enrolled in 24 Month Real-world Study Evaluating Effectiveness of Elocta®

Thursday, January 19, 2017
PR Newswire

STOCKHOLM Sweden Jan 19 2017 PRNewswire Swedish Orphan Biovitrum AB publ Sobi today announces that the first patients have been enrolled in the ASURE study NCT02976753 ASURE is a 24month realworld study evaluating the effectiveness of Elocta compared to conventional FVIII products in the prophyl..

Organovo Announces Release Date for Fiscal Third-Quarter 2017 Financial Results

Thursday, January 19, 2017
GLOBE NEWSWIRE

SAN DIEGO Jan 19 2017 GLOBE NEWSWIRE Organovo Holdings Inc NASDAQONVO Organovo a threedimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology will host a conference call on Thursday February 9 2017 at 500 pm Eastern Time ET to ..

PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases

Thursday, January 19, 2017
PR Newswire

ANNAPOLIS Md and GAITHERSBURG Md Jan 19 2017 PRNewswire PharmAthene Inc NYSE MKT PIP and Altimmune Inc a privatelyheld immunotherapeutics company targeting infectious diseases announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an allstock transacti..

Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO

Thursday, January 19, 2017
PR Newswire

CALGARY Jan 19 2017 PRNewswire Oncolytics Biotech Inc Oncolytics or the Company TSX ONC OTCQX ONCYF today announced that Matt Coffey PhD MBA has been appointed to the role of President and Chief Executive Officer effective immediately Dr Coffey had been serving as the Companys Interim President a..

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin\'s Lymphoma

Thursday, January 19, 2017
PR Newswire

NORTH CHICAGO Ill Jan 19 2017 PRNewswire AbbVie NYSE ABBV a global biopharmaceutical company today announced the US Food and Drug Administration FDA approved IMBRUVICA ibrutinib for the treatment of patients with relapsedrefractory RR marginal zone lymphoma MZL who require systemic therapy and ha..

TOP